Biotech & Pharma
Health Tech
Business & Policy
Health & Science
Team
Exclusive analysis of biotech, pharma, and the life sciences
Topics
Columns
Tools
Events
Team
Account
More
Follow Us
By Damian Garde , Allison DeAngelis and Adam Feuerstein Nov. 17, 2022
How do Alzheimer’s drugs even work? Can biotech people bake? And do we even like one another?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Recorded live from the 2022 STAT Summit, we discuss the failure of an Alzheimer’s disease treatment from Roche, the unexpected success of a competing one for Eisai, and some unpredictable questions from our audience.
For more on what we cover, here’s more on Eisai’s drug; here’s the news on Roche’s treatment; and here’s a series of stories from the STAT Summit.
advertisement
Be sure to sign up on Apple Podcasts, Spotify, Stitcher, Google Play, or wherever you get your podcasts.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].
National Biotech Reporter
Damian covers biotech, is a co-writer of The Readout newsletter, and a co-host of “The Readout LOUD” podcast.
Biotech Startups and Venture Capital Reporter
Allison is a biotech reporter at STAT, covering biopharma startups and venture capital.
Senior Writer, Biotech
Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He’s also a co-host of “The Readout LOUD” podcast.
biotechnology
dementia
statsummit22
This name will appear with your comment
There was an error saving your display name. Please check and try again.
advertisement
Reporting from the frontiers of health and medicine
You’ve been selected! Subscribe to STAT+ for less than $2 per day
Unlimited access to essential biotech, medicine, and life sciences journalism
Subscribe to STAT+ for less than $2 per day
Unlimited access to the health care news and insights you need